Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SARS-CoV Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)

NCT04902911
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 SARS-CoV IgG/IgM antibody rapid test
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 10, 2026, 1:26 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SARS Coronavirus Vaccine (SARS-CoV)

NCT00533741
View directory record Official record
Conditions
Coronavirus (SARS-CoV)
Interventions
Aluminum hydroxide, Placebo, SARS-CoV
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 10, 2026, 1:26 AM EDT
Withdrawn Phase 4 Interventional

Effects of DPP4 Inhibition on COVID-19

NCT04341935
View directory record Official record
Conditions
Coronavirus Infection, Type 2 Diabetes
Interventions
Linagliptin, Insulin regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 10, 2026, 1:26 AM EDT
Recruiting No phase listed Observational

COVID-19 Transmission and Morbidity in Malawi

NCT05973084
View directory record Official record
Conditions
SARS CoV 2 Infection, SARS CoV 2 Vaccination
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
5 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Terminated Phase 1 Interventional

Anti-SARS Cov-2 T Cell Infusions for COVID 19

NCT04401410
View directory record Official record
Conditions
SARS-CoV 2, Viral Infection, COVID 19
Interventions
Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs)
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 10, 2026, 1:26 AM EDT
Completed No phase listed Observational Results available

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793
View directory record Official record
Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
131,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

NCT05886816
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19
Interventions
Mitoquinone/mitoquinol mesylate, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19 Antibody and Reinfection Study

NCT05365750
View directory record Official record
Conditions
COVID-19 Testing
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
4,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

NCT04519437
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
REGN10933+REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

NCT05181683
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 10, 2026, 1:26 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

NCT04323761
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 10, 2026, 1:26 AM EDT
Terminated Phase 1 Interventional

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

NCT05092581
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Stony Brook, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

NCT04358081
View directory record Official record
Conditions
Covid-19
Interventions
HCQ, HCQ+AZT, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Fullerton, California • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 10, 2026, 1:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407
View directory record Official record
Conditions
X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 10, 2026, 1:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections

NCT04623138
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Not listed
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 10, 2026, 1:26 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

NCT05260437
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

NCT05975060
View directory record Official record
Conditions
COVID-19
Interventions
XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 54 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 10, 2026, 1:26 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

NCT05656105
View directory record Official record
Conditions
SARS CoV-2 Post-Acute Sequelae
Interventions
DPA-714 PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 10, 2026, 1:26 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

NCT05437029
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin 3.0, Q-Griffithsin 6.0
Drug
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 10, 2026, 1:26 AM EDT
Terminated No phase listed Observational

Cardiovascular Implications of COVID-19

NCT04435457
View directory record Official record
Conditions
SARS-CoV 2, SARS Pneumonia, COVID-19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Cardiac Complication
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Sep 10, 2026, 1:26 AM EDT